16th Infocus 2018
The most important Latin American event in Clinical Mycology
Montevideo, Uruguay, August 22, 2018. GBT Grupo Biotoscana has a well-established position in the field of systemic antifungals in Latin America. For over 20 years, our company has been committed to providing both innovative therapies and supporting medical education activities that have resulted in thousands of lives saved.
We are the Latin American strategic partner of leading pharmaceutical companies in this field, like Gilead Sciences and Basilea Pharmaceutica. Currently we are preparing for the very important introduction of CRESEMBA® (isavuconazole) a novel broad-spectrum systemic antifungal indicated to treat life-threatening invasive fungal infections. We are also expanding the commercialization from our leading brand AmBisome® (amphotericin B) into the Andean region countries. As a result, GBT is becoming the leading company in providing therapies for invasive fungal infections in the region.
As such, we are preparing to make a significant impact in the upcoming 16th INFOCUS. This is the most important regional academic forum for the exchange of information related to the epidemiology, pathogenesis, diagnosis and treatment of endemic and opportunistic fungal infections.
We will share more information about our plans soon.